Biotechnology

A Maryland firm just got funding for 'universal' stem cells. This isn't just science; it's the blueprint for off-the-shelf cures and a new era of medicine.

With a novel 'gastric bypass in a pill' and a new CFO known for orchestrating lucrative exits, Syntis Bio is gearing up for a high-stakes battle in the booming obesity drug market.

A new fellowship award spotlights how chronic stress rewrites our immune system, pointing to a future where we might reverse a key driver of aging.

Phase 2a data shows a new drug not only stops bone-destroying cancer but heals the damage, with no adverse events. This is a strategic game-changer.

ResVita Bio's new board member signals a major shift. We explore how visionary leadership and living medicine are converging to tackle long-neglected diseases.

We map digital grids and autonomous routes, but what about the biological networks that define half of humanity? An Indian brand is using ancient wisdom to build new infrastructure for women's health.

Consumers demand eco-friendly cleaners but fear they don't work. A new brand, backed by a 74-year legacy, claims its enzyme-based science can finally deliver.

As corporate giants swallow local clinics, one alliance offers a lifeline. Here’s how AllyGPO and BioCareSD use AI and service to help doctors stay independent.

EVERSANA poaches Takeda's Jen Norton to lead a new tech-first unit, signaling a high-stakes bid to dominate the complex life sciences access market.

A new clinical trial for a twice-yearly COPD injection could disrupt a multi-billion dollar market, offering hope to millions and validating a novel biotech strategy.

A new partnership is challenging the supplement status quo with a creatine product that targets brain energy, not just brawn, for a new era in women's health.

Partillion Bioscience’s platform moves beyond single-cell analysis, letting researchers eavesdrop on cellular conversations to reshape drug discovery.

A patient with 'untreatable' colorectal cancer is disease-free for six years after a novel vaccine. But the real revolution may be the biopsy-free tech behind it.

A Cambridge startup is building a 'Common Crawl for the living world,' framing biological data as a strategic weapon in the US-China tech rivalry.

A new clinical trial for a sacroiliac joint device isn't just about technology; it's about a company's bet that rigorous evidence is the best medicine for patients and the healthcare system.

Millions suffer from Dry Eye Disease with few good options. A new clinical trial is now testing a drug tailored to a patient's DNA. Is this the end of trial-and-error?

A new Philips report quantifies AI's benefits in healthcare, from saving time to catching errors. But the path to adoption is fraught with challenges.

FloBiotech and UCLA Health are betting on a new strategy against neurodegeneration: boosting the brain's own defenses. This alliance could redefine a field long plagued by failure.

As a deadly Ebola strain spreads without a vaccine, Dr. Patrick Soon-Shiong's foundation injects $10M and shifts its strategy to direct African aid.

A major study combining two powerful cancer drugs, KEYTRUDA and Trodelvy, has been halted, a setback for patients and a reality check for the industry.